• Molecular NameMethazolamide
  • SynonymNA
  • Weight236.276
  • Drugbank_IDDB00703
  • ACS_NO554-57-4
  • Show 3D model
  • LogP (experiment)0.13
  • LogP (predicted, AB/LogP v2.0)0.78
  • pka7.3
  • LogD (pH=7, predicted)0.6
  • Solubility (experiment)3.5 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.1
  • LogSw (predicted, AB/LogsW2.0)3.46
  • Sw (mg/ml) (predicted, ACD/Labs)1.29
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA138.87
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA carbonic anhydrase inhibitor.
  • Absorption_valueN/A
  • Absorption (description)Methazolamide is well absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding55.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMethazolarnide has a plasma half-life in the dog of 3 hr only a small part (25%) of which is due to renal excretion of unaltered drug. It can conjugate with reduced glutathione and L-cysteine.
  • Half life14 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityElectrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A